Introduction
Adenocarcinoma of the prostate is the most common male cancer and the second leading cause of cancerrelated deaths in men (Cooperberg et al., 2004) . Although extensively scrutinized, no treatment, short of prostatectomy, has proven definitive in eradicating localized tumors or preventing disease recurrence and metastasis Cooperberg et al., 2004) . Based on several factors including organ accessibility, the capacity to monitor disease progression during early stages using prostate specific antigen (PSA) and the lack of survival benefit of the prostate gland, viral-based gene therapies provide a practical treatment option for this disease (Mabjeesh et al., 2002) . However, to realize the promise of gene therapy, identifying a gene therapeutic that does not harm normal cells, can kill not only infected tumor cells, but also has the capacity to induce a potent 'bystander antitumor effect' and to additionally radiosensitize cancer cells would represent an ideal weapon to combat this prevalent male disease and cancer in general (Su et al., 2001 Kawabe et al., 2002; Yacoub et al., 2003c; Chada et al., 2004; Fisher, 2005; Sarkar et al., 2005) . Recent studies indicate that the novel cytokine mda-7/IL-24, which displays the above mentioned antitumor properties, would appear to represent the perfect gene to utilize for the therapy of localized and disseminated prostate tumors (Fisher et al., 2003; Fisher, 2005; Gupta et al., 2005; Lebedeva et al., 2005; Sarkar et al., 2005) .
Hormonally refractive prostate cancers also show resistance to adjuvant treatment modalities, such as radioor chemotherapy, either alone or in combination (Chaudhary et al., 1999; Gopalkrishnan et al., 2001; Mabjeesh et al., 2002; Cooperberg et al., 2004) . A potential reason for this inherent resistance involves elevated expression of members of the bcl-2 family that delimit apoptosis induction by chemotherapy and ionizing radiation (IR), namely bcl-x L and bcl-2 (Reed et al., 1996; Chaudhary et al., 1999; Catz and Johnson, 2003) . Accordingly, numerous studies support a relationship between bcl-x L and bcl-2 expression and prostate cancer development and progression (Colombel et al., 1993; Krajewski et al., 1994 Bauer et al., 1996; Reed et al., 1996; Liu and Stein, 1997; Keshgegian et al., 1998; Bai et al., 1999; Chaudhary et al., 1999; Lebedeva et al., 2000; Li et al., 2001; Catz and Johnson, 2003) . Expression of both Bcl-x L (100%) and Bcl-2 (25%) proteins occur frequently in prostate carcinomas (Colombel et al., 1993; Krajewski et al., 1994 , Bcl-2 staining increases with Gleason grade and represents an indicator of poor prognosis in prostate cancer (Colombel et al., 1993; Bauer et al., 1996; Krajewska et al., 1996) . The expression of bcl-2 is augmented following androgen ablation and correlates with progression of prostate cancer from androgen dependence to androgen independence (McDonnell et al., 1992; Kajiwara et al., 1999) . Moreover, resistance to drug-induced apoptosis in prostate cancer correlates with expression of bcl-x L and bcl-2 (Liu and Stein, 1997; Chaudhary et al., 1999; Lebedeva et al., 2000; Li et al., 2001) .
Previous studies show that delivery of mda-7/IL-24 by a replication incompetent adenovirus, Ad.mda-7, or as a GST-MDA-7 fusion protein selectively kills diverse cancer cells, including prostate tumor cells, without harming normal cells, including prostate epithelial cells and radiosensitizes various cancer cells, such as nonsmall cell lung carcinoma, renal carcinoma and malignant glioma (Su et al., 1998 (Su et al., , 2001 Kawabe et al., 2002; Lebedeva et al., 2002 Lebedeva et al., , 2003 Lebedeva et al., , 2005 Fisher et al., 2003; Yacoub et al., 2003a Yacoub et al., , b, c,2004 Chada et al., 2004; Sauane et al. 2004; Gupta et al., 2005; Saito et al., 2005) . Overexpression of bcl-x L or bcl-2 in prostate carcinoma cells renders these cells resistant to Ad.mda-7-induced apoptosis . We now establish that this resistance to Ad.mda-7 and GST-MDA-7 is reversible in bcl-2 family member overexpressing prostate tumor cells by employing IR. Inhibition of JNK signaling prevents radiation enhancement without thwarting mda-7/IL-24's direct apoptosis-inducing potential suggesting that the mechanism leading to apoptosis induction by mda-7/IL-24 versus that promoting radiation sensitization may proceed through distinct signaling pathways in prostate cancer cells. The present study emphasizes that the therapeutic potential of mda-7/ IL-24 can be augmented by IR with the added advantage of being able to sensitize both radiation-susceptible and mda-7/IL-24-resistant cells to programmed cell death.
Results
Bcl-x L and Bcl-2 overexpressing clones of prostate cancer cells are more radioresistant than parental and neomycinresistant non-overexpressing clones Overexpression of bcl-2 and bcl-x L differentially protects prostate carcinoma cells from undergoing apoptosis following Ad.mda-7 infection . Induction of apoptosis, as monitored by Annexin-V staining, in DU-145 and PC-3 cells by Ad.mda-7 was inhibited when these cells stably overexpress bcl-x L (DU/Bcl-x L and PC/Bcl-x L ), but not bcl-2, whereas mda-7/IL-24-induced apoptosis in LNCaP cells was inhibited by overexpression of bcl-2 (LNCaP/Bcl-2), but not bclx L . These stable bcl-2 family overexpressing clones, two for each prostate cell line, were tested for their response to IR (0.5-6 Gy) versus parental and a neomycin-resistant control clone (Figure 1) . From these studies, it is clear that overexpressing either bcl-x L or bcl-2 affords enhanced survival to prostate carcinoma cells following exposure to a broadrange of doses of IR. In this context, elevated expression of bcl-x L and/or bcl-2 in prostate tumors, a common event in progression of this disease (Colombel et al., 1993; Krajewski et al., 1994 Bauer et al., 1996; Chaudhary et al., 1999) , could in part underlie the resistance of these tumors to chemotherapy-and radiation-induced apoptosis (Liu and Stein, 1997; Lebedeva et al., 2000; Li et al., 2001) .
One clone overexpressing bcl-x L or bcl-2 of each prostate cancer cell type (DU-145, PC-3 and LNCaP) was used in all subsequent experiments, as experiments using two independent overexpressing clones of each cell type demonstrated similar behavior after g-irradiation and infection with Ad.mda-7 (Figure 1 ). Neomycinresistant clones did not differ significantly from parental prostate cancer cells in their response to g-irradiation treatment and therefore a neomycin-resistant clone for each cell type was used as a control for studies to be described below.
Combination of g-irradiation and Ad.mda-7 infection overcomes resistance of bcl-x L and bcl-2 overexpressing clones to both ionizing radiation and mda-7/IL-24 culminating in apoptosis Previous studies confirm that mda-7/IL-24, administered by Ad.mda-7 or as a GST-MDA-7 fusion protein, is a potent radiosensitizer in multiple cancer subtypes, including non-small cell lung carcinoma, breast carcinoma and glioblastoma multiforme (Kawabe et al., 2002; Su et al., 2003; Yacoub et al., 2003b Yacoub et al., , c, 2004 Sauane et al., 2004) . These studies prompted us to test the effect of radiation in combination with Ad.mda-7 or GST-MDA-7 in the context of prostate cancer. Infection of neomycin-resistant clones of DU-145, PC-3 or LNCaP cells with Ad.mda-7 followed by 2 Gy of IR enhanced the loss of survival in all three prostate tumor cell lines (Figure 2a ). The effect of Ad.mda-7 alone and Ad.mda-7 þ 2 Gy IR on decreasing survival was least evident in PC-3 cells, which contain a lower number of Coxsackie adenovirus receptors (CAR) potentially contributing to reduced mda-7/IL-24 transgene expression . The ability of IR (2 Gy) to reduce cell survival is less evident in DU/Bcl-x L , PC/Bclx L or LNCaP/Bcl-2 clones than in comparable parental clones containing a neomycin vector, which do not express elevated levels of bcl-2 family proteins (Figures 1  and 2a) . When both IR and Ad.mda-7 were adminisIonizing radiation enhances therapeutic activity of mda-7/IL-24 Z-Z Su et al tered to DU/Bcl-x L or PC/Bcl-x L cells or to LNCaP/Bcl-2 cells, a statistically significant (Pp0.05) decrease in survival was evident when compared to cells receiving either radiation or mda-7/IL-24 alone. These studies reveal that the combination of IR and Ad.mda-7 can abolish the resistance of prostate cancer cells overexpressing bcl-2 family members to either agent/treatment alone.
It is now firmly established that mda-7/IL-24 selectively induces apoptosis in a broad spectrum of cancer cells in vitro and in vivo (reviewed by Fisher et al., 2003; Fisher, 2005; Gupta et al., 2005; Lebedeva et al., 2005) . To confirm a similar effect when neomycin-resistant prostate carcinoma cells were infected with Ad.mda-7 alone and in combination with IR and in bcl-x L and bcl-2 overexpressing prostate tumor cells when treated with the combination of mda-7/IL-24 and IR, Annexin-V assays were performed ( Figure 2b ). In all three parental neomycin-resistant prostate cancer cell lines, Ad.mda-7 increased the percentage of Annexin-V positive cells as did treatment with 2 Gy of IR. Of direct potential clinical relevance, when used in combination, a statistically significant (Pp0.05) elevation in Annexin-V positive cells resulted (Figure 2b ). In the case of DU/ Bcl-x L , PC/Bcl-x L and LNCaP/Bcl-2 cells, Ad.mda-7 had no effect or marginally enhanced (in PC/Bcl-x L cells) Annexin-V staining, whereas these cells did not display markers of apoptosis when exposed to 2 Gy of IR. However, when Ad.mda-7 was combined with 2 Gy of IR, enhanced Annexin-V staining was apparent in the bcl-2 family overexpressing prostate tumor cells (Figure 2b ). These results confirm that the combination of mda-7/IL-24 and IR applied to bcl-2 family overexpressing prostate tumor cells promotes induction of apoptosis, whereas at the doses employed either agent/treatment alone is devoid of this activity.
Several recent studies confirm that purified GST-MDA-7 fusion protein can promote radiosensitivity in cancer cells Yacoub et al., 2003b Yacoub et al., , c,2004 Sauane et al., 2004) . As observed in infection with Ad.mda-7, GST-MDA-7 reduced survival in parental non-overexpressing bcl-2 family expressing prostate cancer cells, without inducing a similar effect in the bcl-x L or bcl-2 overexpressing prostate cancer cells (Figure 3a) . In contrast, when GST-MDA-7 was combined with radiation, survival was statistically reduced in all the cell types, again providing support for the ability of this novel cytokine to sensitize both inherently susceptible and resistant (because of overexpression of bcl-2 family members) prostate tumor cells to the lethality of IR. As observed with Ad.mda-7, GST-MDA-7 induced apoptosis in neomycin-resistant parental prostate tumor cells and IR enhanced this effect. Similarly, the combination of GST-MDA-7 and IR resulted in enhanced Annexin-V staining in bcl-2 family overexpressing prostate cancer clones (Figure 3b ). Taken together, these data confirm that GST-MDA-7 promotes programmed cell death in prostate cancer cells and this effect is enhanced when combined with IR. Moreover, as with Ad.mda-7 plus IR, the combination of GST-MDA-7 plus IR reverses the resistance of bcl-2 family member overexpressing prostate tumor cells to either agent alone. /Bcl-2 overexpressing clones were exposed to different doses of g-irradiation, and colony forming assays were performed as described in Materials and methods. Survival fraction was determined compared to untreated control cells. Results shown are averages7s.e. using triplicate samples. Experiments were repeated a minimum of three times with qualitatively similar results.
Ionizing radiation enhances therapeutic activity of mda-7/IL-24 Z-Z Su et al JNK signaling is mandatory for the combination of g-irradiation treatment plus Ad.mda-7 or GST-MDA-7 to reduce survival and induce apoptosis in both radiosensitive and radioresistant clones of prostate cancer cells Previous studies illustrate that inhibiting JNK1/2/3 signaling by means of the pharmacological inhibitor SP600125 prevents radiosensitization by Ad.mda-7 in RT2 rat glioma cells . Infection of DU-145, PC-3 or LNCaP cells with 100 PFU/cell of Ad.mda-7 or treatment with GST-MDA-7 decreased cell survival and promoted apoptosis, whereas this effect was not evident in DU/Bcl-X L , PC/Bcl-X L or LNCaP/ Bcl-2 cells (Figures 2a, b and 3a, b) . However, when bcl-2 family overexpressing clones were simultaneously treated with both IR and Ad.mda-7 or GST-MDA-7, decreased cell survival and apoptosis were induced thereby confirming sensitization by the combinatorial treatment of these initially mda-7/IL-24-and IRresistant cells (Figures 2 and 3) . When the same experiments were performed in the presence of SP600125, an inhibitor of JNK 1/2/3 signaling, inhibition of growth and induction of apoptosis were significantly (Pp0.05) inhibited in combination treated bcl-2 family member overexpressing prostate tumor cells (Figures 2 and 3 ). In the case of neomycin-resistant prostate tumor cells not overexpressing antiapoptotic proteins, treatment with SP600125 prevented the radiationsensitization effect, without preventing mda-7/IL-24-mediated lethality. These findings document that radiation-induced growth suppression and induction of apoptosis are likely mediated through distinct pathways than mda-7/IL-24-induced antitumor properties in prostate cancer cells not overexpressing antiapoptotic proteins.
To confirm that JNK activation occurred and was inhibited by SP600125 in prostate tumor cells treated with IR, we determined the level of phospho-JNK and total JNK activity by Western blotting (Figure 4a ). Infection of neomycin-resistant non-overexpressing prostate cancer cells or prostate cancer cells displaying elevated expression of bcl-2 family proteins with Ad.vec or Ad.mda-7 did not increase the levels of phospho- Figure 2 Combination of Ad.mda-7 and g-irradiation induces killing and apoptosis in resistant Bcl-x L -and Bcl-2-overexpressing clones of prostate cancer cells. (a) Effect of single and combination treatment with Ad.mda-7 and g-irradiation on growth of neomycinresistant and Bcl-x L -and Bcl-2-overexpressing clones of prostate cancer cells in the presence or absence of the JNK 1/2/3 inhibitor, SP600125. Neomycin-resistant and Bcl-x L /Bcl-2 overexpressing clones of prostate cancer cells were infected with Ad.mda-7 virus or empty adenovector virus (Ad.vec) and the next day were exposed to 2 Gy of g-irradiation. 2 h before the radiation treatment, infected cells were treated with 2 mM of SP600125 or an equivalent dose of vehicle (DMSO) as a control. Colony forming assays were performed as described in the Materials and methods section, and survival fraction was determined compared to untreated control cells. Results shown are averages7s.e. of triplicate samples. Statistical significance was determined by a Student's t-test, and a P-value of o0.05 is indicated by an asterisk. (b) Combination treatment with Ad.mda-7 and g-irradiation induces apoptosis in neomycin-resistant and Bclx L and Bcl-2-overexpressing clones of prostate cancer cells. Cells were treated as described in a, and 24 h after the radiation treatment were stained with Annexin-V followed by FACS assay as described in Materials and methods. Results shown are averages from three independent experiments7s.e. Statistically significant results with a P-value of o0.05 are indicated by an asterisk. JNK-inhibitor, SP600125 abrogates effect of g-irradiation treatment in both radiosensitive and radioresistant clones of prostate cancer cells. All experiments were performed a minimum of three times.
Ionizing radiation enhances therapeutic activity of mda-7/IL-24 Z-Z Su et al JNK. Similarly, treatment with GST or GST-MDA-7 did not alter the levels of phospho-JNK in neomycinresistant or bcl-2 family overexpressing prostate tumor cells (data not shown). In contrast, treatment of the various prostate cancer cells with IR enhanced JNK activation (Figure 4a ). Moreover, when these assays were performed in the presence of SP600125, the level of phopho-JNK induced by IR was reduced to basal levels. These data confirm that IR, but not mda-7/IL-24, induces JNK activation in prostate tumor cells and this IR-induced activation is extinguished in the presence of the JNK inhibitor SP600125 (Figure 4a ).
Combination of g-irradiation and Ad.mda-7 does not affect levels of MDA-7/IL-24 protein while downregulating antiapoptotic Bcl-2 family protein expression A potential mechanism by which radiation promotes apoptosis induction in bcl-2 family member overexpressing prostate cancer cells could involve changes in the levels of MDA-7/IL-24 protein. To test this possibility, Western-blotting experiments were conducted in neomycin-resistant and bcl-2 family overexpressing prostate cancer cells infected with Ad.mda-7, with and without treatment with IR ( Figure 4b ). Except for changes in expression that might be linked to clonal variation, in most of the clones no significant change in the amount of MDA-7/IL-24 was apparent as a consequence of IR. Moreover, when these assays were performed in the presence of SP600125, no consistent alteration in expression levels of MDA-7/IL-24 was evident with or without radiation (Figure 4b ). These results indicate that the ability of IR to induce apoptosis in bcl-2 family member overexpressing prostate tumor cells is not a consequence of augmentation in the level of this apoptosis-inducing protein.
In several tumor models, including prostate cancer but not in normal cellular counterparts, infection with Ad.mda-7 changes the ratio of pro-apoptotic to antiapoptotic proteins thereby shifting the balance from Figure 3 The combination of recombinant GST-MDA-7 protein and g-irradiation sensitizes Bcl-x L and Bcl-2-overexpressing clones of prostate cancer cells to killing and apoptosis, a process, which is blocked by inhibiting JNK signaling. (a) The combination of GST-MDA-7 and radiation decreases viability in resistant Bcl-x L and Bcl-2 overexpressing clones of prostate cancer cells. Neomycinresistant and Bcl-x L /Bcl-2 overexpressing clones of prostate cancer cells were treated with recombinant GST-MDA-7 or GST protein (30 ng/ml) and the next day were exposed to 2 Gy of g-irradiation. 2 h before the radiation treatment, cells were treated with 2 mM of SP600125 or equivalent dose of vehicle (DMSO) as a control. Colony forming assays were performed as described in Materials and methods, and survival fraction was determined compared to untreated control cells. Results shown are averages7s.e. of triplicate experiments, using triplicate samples for each experiment. Statistical significance was determined by a Student's t-test, and a P-value of o0.05 is indicated by an asterisk. (b) GST-MDA-7 and radiation induce apoptosis in resistant Bcl-x L -and Bcl-2 overexpressing clones of prostate cancer cells. Cells were treated as described in 3a, and 24 h after the radiation treatment were stained with Annexin-V followed by FACS assay as described in the Materials and methods section. Replicate experiments measuring Annexin-V binding varied by p10%. Qualitatively similar results were obtained in two additional experiments. Statistically significant results with a P-value of o0.05 are indicated by an asterisk. The JNK-inhibitor, SP600125 abrogates the effect of g-irradiation treatment in both radiosensitive and radioresistant clones of prostate cancer cells.
Ionizing radiation enhances therapeutic activity of mda-7/IL-24 Z-Z Su et al Figure 4 The JNK inhibitor SP600125 prevents pJNK phosphorylation following radiation treatment but does not influence MDA-7/ IL-24 protein synthesis. Neomycin-resistant and Bcl-x L /Bcl-2 overexpressing clones of prostate cancer cells were infected with Ad.mda-7 virus or Ad.vec and the next day were exposed to 2 Gy of g-irradiation. 2 h before the radiation treatment, infected cells were treated with 2 mM of SP600125 or an equivalent dose of vehicle (DMSO) as a control. The next day, cell lysates were collected in RIPA buffer and Western-blotting assays were performed as described in the section on Materials and methods to determine pJNK phosphorylation (a) and MDA-7/IL-24 protein expression (b). The membranes were restained with total JNK antibody (a) as well as EF-1a (b) to confirm equal loading. survival to death and providing a potential mechanism for selective induction of apoptosis in cancer cells (Su et al., 1998 (Su et al., , 2001 Kawabe et al., 2002; Lebedeva et al., 2002 Lebedeva et al., , 2003 . On the basis of this consideration, we determined the effect of Ad.mda-7, with and without IR, on the levels of Bcl-2 and Bcl-x L proteins in neomycinresistant and bcl-2 family member overexpressing prostate cancer clones ( Figure 5 ). In addition, as SP600125 can block the combinatorial action of Ad.mda-7 in inducing a reduction of survival and promoting apoptosis in both parental and bcl-2 family member overexpressing clones, the effect of this JNK inhibitor was also studied. In the case of the DU/neo clone, infection with Ad.mda-7, alone and to a much greater degree with IR decreased the levels of both Bcl-2 and Bcl-x L proteins, whereas SP600125 inhibited these changes ( Figure 5 ). In DU/Bcl-x L cells, the combination of Ad.mda-7 and IR predominantly inhibited expression of the Bcl-x L protein and this decrease was also blocked by SP600125. In PC/neo and PC/Bcl-x L clones, the combination of Ad.mda-7 and IR also downregulated Bcl-x L protein levels and these changes were again blocked by SP600125. In the case of PC/Bcl-x L , treatment with either Ad.mda-7 or IR alone did not significantly alter the levels of the Bcl-x L proteins ( Figure 5 ). In LNCaP/neo cells, Ad.mda-7 alone and in combination with IR downregulated both Bcl-2 and Bcl-x L proteins and the changes induced by IR were ameliorated by SP600125. In the case of the LNCaP/ Bcl-2 clone, although the combination of Ad.mda-7 plus IR downregulated both antiapoptotic genes, Ad.mda-7 or IR alone did not change the levels of Bcl-2 or Bcl-x L in this clone. In the combination-treated LNCaP/ Bcl-2 clone, addition of SP600125 returned expression of Bcl-2 to levels observed in Ad.vec-infected cells. We have also determined the effect of radiation with and without infection with Ad.mda-7 and with and without treatment with SP600125 on the levels of bcl-2, bcl-x L and gapdh mRNA in DU-145/neo and DU-145/Bcl-xL cells (data not shown). These results indicate no statistically significant changes in the levels bcl-2, bclx L and gapdh mRNA following any of the experimental conditions (Ad.vec or Ad.mda-7 infection, with or without irradiation or treatment with SP600125). These results suggest that the changes observed in expression of the antiapoptotic genes following Ad.mda-7 infection, alone and with radiation, most likely occur on a posttranscriptional and/or post-translational level. All of these findings indicate that the combination of Ad.mda-7 and IR induces changes in the profile of antiapoptotic genes, a process that is blocked by inhibiting JNK signaling, suggesting a potential involvement of these changes in inducing apoptosis by this combinatorial treatment (Ad.mda-7 þ IR) in the context of inherently sensitive prostate carcinoma cells and bcl-2 family member overexpressing resistant clones.
Combination of g-irradiation and GST-MDA-7 treatment downregulates antiapoptotic Bcl-2 family protein expression Similar changes in the ratio of pro-apoptotic to antiapoptotic members of Bcl-family proteins were detected in prostate tumor cells after combination treatment with IR and GST-MDA-7 (data not shown). GST-MDA-7 protein treatment decreased Bcl-x L and, to a smaller extent, Bcl-2 levels in DU/neo cells, whereas its combination with IR dramatically decreased Bcl-x L levels in these cells. In contrast, no effect was observed in a DU/Bcl-2 overexpressing clone after treatment with only GST-MDA-7 protein. However, a combination of protein and IR led to a significant downregulation of Bcl-x L protein in this clone which resulted in increased sensitivity of this clone to the treatment. Similarly, GST-MDA-7 alone slightly downregulated Bcl-x L expression in the PC/neo and the PC/Bcl-x L clone, whereas combination with IR augmented this effect dramatically. Both Bcl-2 and Bcl-x L levels were decreased following GST-MDA-7 treatment in LNCaP/neo and, to a lesser extent, in LNCaP/Bcl-2 clones. The combination of GST-MDA-7 with IR dramatically decreased levels of Bcl-x L protein in the neomycin-resistant clone and decreased expression of both antiapoptotic proteins in the LNCaP/Bcl-2 clone. Inhibiting JNK signaling with SP600125 abolished the effect of IR but not GST-MDA-7 on the Bcl-2/Bcl-x L profile in all three of the cell lines studied.
These experiments confirm that the combination of GST-MDA-7 and IR decreases the levels of expression of antiapoptotic genes both in sensitive prostate Figure 5 The combination of Ad.mda-7 infection and g-irradiation downregulates Bcl-x L and/or Bcl-2 protein levels in prostate cancer cells and their Bcl-2-and Bcl-x L -overexpressing resistant clones. Cells were treated as indicated, cell lysates were collected 48 h after the radiation treatment, and Western blotting was performed as described in Materials and methods. Membranes were reprobed with EF-1a antibody to confirm equal loading.
Ionizing radiation enhances therapeutic activity of mda-7/IL-24 Z-Z Su et al carcinoma cells and in bcl-2/Bcl-x L overexpressing resistant clones. The changes in bcl-2 gene family members are blocked by inhibiting JNK signaling, and these changes are involved in inducing apoptosis by this combinatorial treatment.
Discussion
We presently illustrate an interesting and potentially clinically useful observation that a combination of mda-7/IL-24 with IR promotes apoptosis not only in prostate tumor cells that are intrinsically sensitive to these agents, but also in prostate tumor cells acquiring resistance to both of these agents as a consequence of overexpression of bcl-2 family members. Studies using the specific inhibitor SP600125 indicate that blocking JNK signaling prevented radiosensitization but not apoptosis induction by mda-7/IL-24 in neomycin-resistant prostate carcinoma cells. In bcl-2 family overexpressing prostate carcinoma cells, IR or mda-7/IL-24 (either as Ad.mda-7 or as GST-MDA-7) alone did not affect cell growth but a combination of both induced apoptosis that could be inhibited by SP600125. These finding argue that the signaling pathway(s) by which Ad.mda-7 and GST-MDA-7 inhibit growth and induce apoptosis in prostate tumor cells (not displaying greatly elevated levels of bclx L or bcl-2) may be distinct from those induced by radiation, which involves JNK signaling. In contrast, the combinatorial effect of IR plus mda-7/IL-24 in bcl-2 family overexpressing prostate tumor cells requires JNK signaling. In the case of non-small cell lung carcinoma cells, Ad.mda-7 induces JNK-phosphorylation, which was not enhanced further by treatment with IR (Kawabe et al., 2002) . When treated with curcumin, which can inhibit JNK 1/2/3 signaling, JNK-phosphorylation was inhibited and the radiosensitizing effects of IR were eliminated (Kawabe et al., 2002) . In the case of RT2 malignant rat glioma cells, both IR and mda-7/IL-24 did not induce JNK phsophorylation, whereas the combination treatment promoted JNK phosphorylation . In this cell type, pretreatment with SP600125 blocked both JNK phosphorylation and the enhancing effect of IR on decreasing cell survival . In total, these studies strongly support a potential role for JNK signaling in the radiosensitization effects of mda-7/IL-24 but they also indicate that treatment with mda-7/IL-24, in the absence or presence of IR, results in complex cellular changes, some of which may be cell-type specific.
The role of JNK activation in mediating radiation enhanced Ad.mda-7-and GST-MDA-7-induced apoptosis in bcl-2-and bcl-xL overexpressing prostate cancer cells remains to be defined. The p46/p54 serine/ threonine kinases, c-Jun N-terminal kinases (also called stress-activated protein kinases), are members of the MAP kinase-related family and represent a common pathway shared by cell proliferation and stress-response signaling (Karin, 1998) . The JNK kinase cascade can be induced by various mitogenic factors including growth factors, oncogenic Ras, phorbol esters, and T-cell activation signaling. JNK is also activated by additional stimuli, including protein synthesis inhibition, osmotic shock and proinflammatory cytokines (reviewed by Karin, 1998; Dent et al., 2003a) . Moreover, g-and UV-radiation cause prominent JNK activation (Chen et al., 1996a, b) , which may involve radiation-induced activation of sphingomyelinase with subsequent increases in ceramide levels that promote this effect. Additional activators of the JNK/SAPK signaling cascade, include small GTP-binding proteins, tyrosine kinases, ASK-1 (apoptosis signal-regulating kinase), ATM (ataxia-telagectasia-mutated) and cABL proteins (reviewed by Dent et al., 2003a, b) ). Finally, JNK activation could follow the activation of effector procaspases, which in some cell types plays a key role in apoptotic processes (reviewed by Dent et al., 2003a, b) . In the context of the present work, several studies have demonstrated translocation of activated JNK to mitochondria and its further association with Bcl-family proteins. Activated JNK has been shown to phosphorylate mitochondrial Bcl-2 and Bcl-x L promoting apoptosis without changing the levels of these proteins (Maundrell et al., 1997; Kharbanda et al., 2000) . Overexpression of these antiapoptotic proteins disrupts JNK proapoptotic signaling (Srivastava et al., 1999) , whereas radiation may enhance JNK activation overriding this inhibition in apoptosis induction induced by MDA-7/IL-24 in bcl-family overexpressing resistant prostate tumor cells.
A potential target for mda-7/IL-24's selective antitumor activity involves activation of the mitochondrial (intrinsic) apoptotic pathway uniquely in cancer cells (Fisher et al., 2003; Fisher, 2005; Lebedeva et al., 2005) . In the case of prostate tumor cells, overexpression of the antiapoptotic proteins Bcl-x L and Bcl-2 differentially protects cells from growth suppression and apoptosis induction by Ad.mda-7 and GST-MDA-7 (Figure 3) . Overexpression of bcl-x L and not bcl-2 in DU-145 and PC-3 cells affords protection from mda-7/IL-24-induced apoptosis . In contrast, in LNCaP cells bcl-2 but not bcl-x L mediates resistance to apoptosis induction by this novel cytokine . The mechanism by which these structurally similar molecules elicit differential protection from mda-7/IL-24 in specific prostate tumor cell lines is presently under investigation. Similarly, the mechanism by which IR can override this resistance remains to be determined. We have begun investigating both of these processes and the present data argues that potential changes in the levels of Bcl-x L and Bcl-2 proteins following IR, alone and in combination with mda-7/IL-24, are JNK signaling dependent (Figures 4 and 5) . One possibility, currently under investigation, is that post-transcriptional changes in the levels of antiapoptotic proteins, in combination with potential increases in the levels of defined pro-apoptotic proteins , in IR plus mda-7/IL-24 treated cells may swing the balance from survival to death.
In summary, a combination of IR plus mda-7/IL-24, administered by adenovirus or as a purified GST-fusion protein, enhances apoptosis induction in prostate tumor cells and nullifies resistance to programmed cell death of bcl-2 family overexpressing prostate cancer cells to either of these agents alone. As overexpression of bcl-x L and bcl-2 represent common occurrences in prostate cancer development and progression, and these genes may directly contribute to therapeutic resistance in these tumors, the present studies provide support for a strategy combining IR and mda-7/IL-24 for the treatment of primary, hormone-responsive and hormone-refractive prostate cancer.
Materials and methods

Cell lines, virus infection and radiation protocols
Human DU-145, PC-3 and LNCaP prostate carcinoma cells were obtained from the ATCC and cultured in RPMI 1640 supplemented with 10% FBS, 1% MEM, sodium pyruvate, and non-essential amino acids. P69; an SV40-immortalized human prostate epithelial cell line was provided by Dr Joy Ware (Virginia Commonwealth University, VA) and grown under serum-free conditions as described previously (Bae et al., 1994) . Bcl-2 and Bcl-x L stable overexpressing clones of each prostate cancer cell line were generated and cultured as described . The recombinant replication-defective Ad.mda-7 virus was created in two steps as described previously (Su et al., 1998) and plaque purified by standard procedures. Cells were infected with 100 PFU/cell of Ad.mda-7 or Ad.vec (30 PFU/cell for LNCaP cells) and analysed as described. Cells were irradiated with 0.5-6 Gy of IR using a 137 Cs g-irradiation source.
GST-MDA-7 production Standard cloning procedures were used to generate a bacterial expression vector comprising in-frame fusion of the mda-7/IL-24 open reading frame (ORF) 3 0 to the GST ORF in GST-4T2 vector (Amersham Pharmacia, NJ, USA), using BamH1 and Not1 sites introduced into the mda-7/IL-24 ORF by PCR as previously described (Sauane et al., 2004) . GST and GST-MDA-7 proteins were produced in bacteria, purified and activity confirmed as described (Sauane et al., 2004) .
Clonogenic survival assay Cells were treated as described in the section on Results and Figure legends . The following day, after trypsinization and counting, cells were replated in 60-mm dishes (300 cells per dish) in triplicates. After 2 or 3 weeks, cells were fixed with 4% formaldehyde and stained with 5% (w/w) solution of Giemsa stain in water. Colonies X50 cells were scored and counted. In studies employing irradiation and the inhibitor SP600125, cells were pretreated before irradiation and during radiation recovery before determining effects on colony formation.
Annexin-V binding assays Cells were trypsinized, washed once with complete medium and stained with FITC-labeled Annexin-V (kit from Oncogene Research Products, Boston, MA) according to the manufacturer's instructions. Flow cytometry was performed immediately after staining.
Western-blotting assays
Cell lines were grown on 10-cm plates and protein extracts were prepared with RIPA buffer containing a cocktail of protease inhibitors. A measure of 50 mg of protein was applied to 12% SDS-PAGE and transferred to nitrocellulose membranes. The membranes were probed with polyclonal or monoclonal antibodies to mda-7/IL-24, bcl-2, bcl-x L , phospho-JNK, total JNK and EF-1a Yacoub et al., 2003b) .
Statistical analysis
All of the experiments were performed at least three times. Results are expressed as mean7s.e. Statistical comparisons were made using an unpaired two-tailed Student's t-test. A Po0.05 was considered significant.
Abbreviations mda-7, melanoma differentiation associated gene-7; IL-24, interleukin-24; Ad.mda-7, adenovirus administered mda-7; PFU, plaque-forming units; IR, ionizing radiation; JNK, cJun N-terminal kinase.
